Clinical Trial Update: A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model [Phase 2]

View source ↗

Summary

Phase 2 trial update showing completion of a study evaluating JNJ 40929837 for asthma using a bronchial allergen challenge model.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• JNJ 40929837

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Asthma | Phase 2 | Status: COMPLETED